Verition Fund Management
NXTM

Verition Fund Management’s NxStage Medical Inc. NXTM Stock Holding History

Verition Fund Management’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,800
Closed -$317K – 1444
2017
Q1 		$317K Buy
+11,800
New +$326K 0.03% 817

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's NXTM Position: Q2 2017 in Review

Verition Fund Management sold out of NxStage Medical Inc. (NXTM) in Q2 2017, closing a stake of 11,800 shares — an estimated $317K sold.

Verition Fund Management first reported a position in NXTM in Q1 2017 and held it in 1 quarter. The position peaked at $317K in Q1 2017. 163 funds tracked by Wall St. Rank hold NXTM as of Q2 2017.

  • Verition Fund Management reported no remaining NxStage Medical Inc. position as of Q2 2017 after selling out during the quarter.
  • Verition Fund Management sold 11,800 NxStage Medical Inc. shares in Q2 2017, an estimated $317K.
  • Verition Fund Management first reported a position in NxStage Medical Inc. in Q1 2017 and held it in 1 quarter.
  • Verition Fund Management's NxStage Medical Inc. position peaked at $317K in Q1 2017.
  • 163 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q2 2017.

Based on Verition Fund Management's 13F filing for Q2 2017, filed 15 Aug 2017.